Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China

PLM60 was estimated to be a cost-effective treatment for R/R PTCL compared with CS055 from a Chinese healthcare perspective, which provided patients with an effective and cost-saving treatment option.